Stock data
| Market cap. | NOK6037.7m |
| Last close | NOK142.00 |
| High / Low (52 weeks) | NOK214.2 / NOK124.4 |
| Stock market listing | OSE |
| Forecast net cash (NOKm) | 632.6 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 5.97 | (8.62) | (4.96) |
| Relative * | 11.82 | (1.61) | 8.42 |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (NOKm) | EBITDA (NOKm) | PBT (NOKm) | EPS (öre) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2010A | 270.9 | 26.1 | 23.1 | 58.47 | 242.9 | N/A |
| 2011A | 250.4 | 23.7 | 19.9 | 49.75 | 285.4 | N/A |
| 2012E | 641.3 | 338.5 | 333.8 | 791.37 | 17.9 | 37.9 |
| 2013E | 711.8 | 257.0 | 251.1 | 590.64 | 24.0 | 46.4 |
Last updated on 16/05/2012
Latest research
50/50 vision
Update | Pharmaceutical & Healthcare | 14/05/2012
Fully fledged business
Outlook | Pharmaceutical & Healthcare | 28/02/2012
Flesh on the bones
Update | Pharmaceutical & Healthcare | 02/02/2012
SoC potential in CRPC
Update | Pharmaceutical & Healthcare | 01/11/2011
Xgeva now in its sights?
Update | Pharmaceutical & Healthcare | 18/10/2011
Launch timing clearer
Review | Pharmaceutical & Healthcare | 16/08/2011
Positive ALSYMPCA data
Review | Pharmaceutical & Healthcare | 07/06/2011
First thorium MAb deal
Update | Pharmaceutical & Healthcare | 06/04/2011
Breast cancer next
Review | Pharmaceutical & Healthcare | 14/02/2011
Great expectations
Outlook | Pharmaceutical & Healthcare | 06/01/2011
Norwegian blue chip
Review | Pharmaceutical & Healthcare | 17/08/2010
Prostate combo study
Review | Pharmaceutical & Healthcare | 22/04/2010
Investment summary
Having exercised its option to co-promote Alpharadin, Algeta is set to enter the commercialisation process with Bayer on a 50/50 basis in the US. The project is on track to be filed with the FDA in mid-2012 – an event that will trigger a €50m milestone payment from Bayer. While the specific claims sought in the US label have yet to be confirmed, we believe that Alpharadin will become a standard of care in metastatic castration-resistant prostate cancer.
Last updated on 14/05/2012
Industry outlook
Algeta is the world leader in the development of alpha-pharmaceuticals. Interest around Alpharadin is growing after positive Phase III data and the approvals for metastatic castration-resistant prostate cancer of Dendreon's Provenge, Sanofi's Jevtana and J&J's Zytiga.
Last updated on 23/04/2012
Key management
| Stein Holst Annexstad , Chairman |
| Andrew Kay , CEO |
| Øystein Soug , CFO |
Company address
| PO Box 54 Kjelsås Oslo NO-0411 Sweden +47 23 00 79 85 View website |
